Using subclass mapping, we compared the TCGA expression profiles of the three immune subtypes with another published dataset (GSE91061) from 47 patients with melanoma who received PD-1 inhibitors or cytotoxic T-lymphocyte-associated protein-4 inhibitors [31]. Here, CTLA4 is linked to melanoma.